Roivant Sciences (NASDAQ:ROIV) Director Daniel Allen Gold Sells 12,380 Shares of Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) Director Daniel Allen Gold sold 12,380 shares of the stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $35.28, for a total value of $436,766.40. Following the completion of the sale, the director owned 13,689,166 shares in the company, valued at approximately $482,953,776.48. This trade represents a 0.09% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Daniel Allen Gold also recently made the following trade(s):

• On Monday, June 29th, Daniel Allen Gold sold 800,000 shares of Roivant Sciences stock. The stock was sold at an average price of $34.55, for a total transaction of $27,640,000.00.
• On Friday, June 26th, Daniel Allen Gold sold 625,783 shares of Roivant Sciences stock. The shares were sold at an average price of $34.00, for a total transaction of $21,276,622.00.

Roivant Sciences Trading Up 1.9%

Shares of NASDAQ:ROIV traded up $0.66 on Tuesday, hitting $35.39. The company had a trading volume of 6,160,114 shares, compared to its average volume of 5,917,255. The stock has a market cap of $25.45 billion, a price-to-earnings ratio of -58.98 and a beta of 1.13. The stock has a 50 day moving average price of $29.88 and a 200 day moving average price of $27.02. Roivant Sciences Ltd. has a 1-year low of $10.70 and a 1-year high of $35.90.

Roivant Sciences (NASDAQ:ROIV) last posted its earnings results on Wednesday, May 20th. The company reported $0.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.57. The company had revenue of $2.52 million during the quarter, compared to analysts’ expectations of $3.41 million. Roivant Sciences had a negative net margin of 3,629.19% and a negative return on equity of 20.54%. During the same quarter last year, the company posted ($0.29) EPS. Sell-side analysts anticipate that Roivant Sciences Ltd. will post -1.83 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

ROIV has been the subject of a number of research analyst reports. Guggenheim boosted their price objective on Roivant Sciences from $30.00 to $36.00 and gave the stock a “buy” rating in a report on Tuesday, May 26th. Weiss Ratings lowered Roivant Sciences from a “sell (d)” rating to a “sell (d-)” rating in a research note on Friday, May 22nd. Citigroup lifted their price target on Roivant Sciences from $35.00 to $42.00 and gave the stock a “buy” rating in a report on Thursday, May 21st. Piper Sandler reissued an “overweight” rating on shares of Roivant Sciences in a research report on Thursday, May 21st. Finally, Sanford C. Bernstein started coverage on shares of Roivant Sciences in a research note on Friday, March 20th. They issued an “outperform” rating and a $35.00 price target on the stock. Ten research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $33.59.

Institutional Investors Weigh In On Roivant Sciences

A number of hedge funds and other institutional investors have recently made changes to their positions in ROIV. SBI Securities Co. Ltd. boosted its stake in shares of Roivant Sciences by 1,740.3% in the fourth quarter. SBI Securities Co. Ltd. now owns 1,233 shares of the company’s stock valued at $27,000 after buying an additional 1,166 shares during the period. Allworth Financial LP increased its stake in Roivant Sciences by 48.1% during the 3rd quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock worth $27,000 after acquiring an additional 583 shares during the period. Kestra Advisory Services LLC bought a new position in Roivant Sciences during the 4th quarter worth $47,000. Parallel Advisors LLC raised its holdings in Roivant Sciences by 33.7% in the 1st quarter. Parallel Advisors LLC now owns 2,065 shares of the company’s stock valued at $57,000 after acquiring an additional 520 shares in the last quarter. Finally, CIBC Private Wealth Group LLC lifted its position in shares of Roivant Sciences by 7,614.3% during the 4th quarter. CIBC Private Wealth Group LLC now owns 2,700 shares of the company’s stock valued at $59,000 after acquiring an additional 2,665 shares during the period. 64.76% of the stock is currently owned by institutional investors and hedge funds.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.